Limited-Time Gift Shop To Feature Blue Bottle’s Craft Instant Coffee, Premium Matcha, and Select Merchandise at Japanese Fashion Retailer LUMINE’s new Flagship Location in Raffles City Center. OAKLAND, Calif., Aug. 8, 2024 /PRNewswire/ — Blue Bottle Coffee is set to make its debut in Southeast Asia, with a gift shop at the new LUMINE Singapore global […]
Category Archives: Pr Newswire
The low-voltage inverter is specifically designed for small C&I installations DENVER, Aug. 8, 2024 /PRNewswire/ — GoodWe Technologies Co Ltd (“GoodWe”) (688390:SHH), a global leader in solar inverters and smart energy solutions, launched its LVSMT-US inverter to meet the needs of small C&I installations. To flexibly meet a variety of capacities and local grid requirements, the […]
Pr Newswire
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
07
Aug
Aug
BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter […]
Pr Newswire
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
07
Aug
Aug
THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 – 12, 2024 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. […]
07
Aug
Aug
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York City, New York on Tuesday, August 13, 2024, at 11 AM […]
Pr Newswire
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
07
Aug
Aug
Conference Call to Begin Today at 9:00 a.m. (ET) 2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023 YTD 2024 Total revenues of $139M; +55% vs. YTD 2023 YTD 2024 Net income of $9 million; Non-GAAP net income of $29 million Advances two orphan lung programs to human studies MNKD-101 Phase 3 clinical trial […]
07
Aug
Aug
SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024. “We are excited to welcome Francis to […]
SANTA CLARA, Calif., Aug. 7, 2024 /PRNewswire/ — Tuya Inc. (“Tuya” or the “Company”) (NYSE: TUYA; HKEX: 2391), a global leading cloud platform service provider, today announced that it will report its second quarter 2024 unaudited financial results after the market closes on Monday, August 26, 2024. Tuya’s management will hold a conference call at 08:30 […]
GUELPH, ON, Aug. 7, 2024 /PRNewswire/ — Canadian Solar Inc. (the “Company” or “Canadian Solar”) (NASDAQ: CSIQ) today announced that e-STORAGE, which is part of the Company’s majority-owned subsidiary CSI Solar Co., Ltd. (“CSI Solar”), has been awarded a turnkey EPC contract for 100 MW / 200 MWh energy storage solutions by Fotowatio Renewable Ventures […]
Engagement is part of I-Mab’s commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, Md., Aug. 7, 2024 /PRNewswire/ — I-Mab (NASDAQ: IMAB) (“I-Mab”, the “Company”), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the […]